How to treat splenic marginal zone lymphoma (SMZL) in patients unfit for surgery or more aggressive therapies: experience in 30 cases

References

• Troussard X, Valensi F, Duchayne E, Garand R, Felman P, Tulliez M, et al. Splenic lymphoma with villous lymphocytes: clinical presentation, biology and prognostic factors in a series of 100 patients. Br J Haematol. 1996;93:731–736.10.1046/j.1365-2141.1996.d01-1711.x
   PubMed Web of Science ®Google Scholar
• Felman P, Thieblemont C, Pradier T, Baseggio L, Bryon PA, Salles G, et al. Non-MALT marginal zone B-cell lymphomas: a description of clinical presentation and outcome in 124 patients. Blood. 2000;95:1950–1956.
   PubMed Web of Science ®Google Scholar
• Thieblemont C, Felman P, Callet-Bauchu E, Traverse-Glehen A, Salles G, Berger F, et al. Splenic marginal-zone lymphoma: a distinct clinical and pathological entity. Lancet Oncol. 2003;4:95–103.10.1016/S1470-2045(03)00981-1
   PubMed Web of Science ®Google Scholar
• Mulligan SP, Matutes E, Dearden C, Catovsky D. Splenic lymphoma with villous lymphocytes: natural history and response to therapy in 50 cases. Br J Haematol. 1991;78:206–209.10.1111/j.1365-2141.1991.tb04417.x
   PubMed Web of Science ®Google Scholar
• Chacón JI, Mollejo M, Muñoz E, Algara P, Mateo M, Lopez L, et al. Splenic marginal zone lymphoma: clinical characteristics and prognostic factors in a series of 60 patients. Blood. 2002;100:1648–1654.
   PubMed Web of Science ®Google Scholar
• Arcaini L, Lazzarino M, Colombo N, Burcheri S, Boveri E, Paulli M, et al. Splenic marginal zone lymphoma: a prognostic model for clinical use. Blood. 2006;107:4643–4649.10.1182/blood-2005-11-4659
   PubMed Web of Science ®Google Scholar
• Franco V, Florena AM, Stella M, Rizzo A, Iannitto E, Quintini G, et al. Splenectomy influences bone marrow infiltration in patients with splenic marginal zone cell lymphoma with or without villous lymphocytes. Cancer. 2001;91:294–301.10.1002/(ISSN)1097-0142
   PubMed Web of Science ®Google Scholar
• Thieblemont C, Davi F, Noguera ME, Brière J, Bertoni F, Zucca E, et al. Splenic marginal zone lymphoma: current knowledge and future directions. Oncology. 2012;26:194–202.
   PubMed Web of Science ®Google Scholar
• Arcaini L, Orlandi E, Scotti M, Brusamolino E, Passamonti F, Burcheri S, et al. Combination of rituximab, cyclophosphamide, and vincristine induces complete hematologic remission of splenic marginal zone lymphoma. Clin Lymphoma. 2004;4:250–252.10.3816/CLM.2004.n.005
   PubMedGoogle Scholar
• Cervetti G, Galimberti S, Pelosini M, Ghio F, Cecconi N, Petrini M. Significant efficacy of 2-chlorodeoxyadenosine +/– rituximab in the treatment of splenic marginal zone lymphoma (SMZL): extended follow-up. Ann Oncol. 2013 Jun 10. Epub ahead of print. 24:2434–2438.
   PubMed Web of Science ®Google Scholar
• Bennett M, Sharma K, Yegena S, Gavish I, Dave HP, Schechter GP. Rituximab monotherapy for splenic marginal zone lymphoma. Haematologica. 2005;90:856–858.
   PubMed Web of Science ®Google Scholar
• Tsimberidou AM, Catovsky D, Schlette E, O’Brien S, Wierda WG, Kantarjian H, et al. Outcomes in patients with splenic marginal zone lymphoma and marginal zone lymphoma treated with rituximab with or without chemotherapy or chemotherapy alone. Cancer. 2006;107:125–135.10.1002/(ISSN)1097-0142
   PubMed Web of Science ®Google Scholar
• Fabbri A, Gozzetti A, Lazzi S, Lenoci M, D’Amuri A, Leoncini L, et al. Activity of rituximab monotherapy in refractory splenic marginal zone lymphoma complicated with autoimmune hemolytic anemia. Clin Lymphoma Myeloma. 2006;6:496–499.10.3816/CLM.2006.n.033
   PubMedGoogle Scholar
• Bolam S, Orchard J, Oscier D. Fludarabine is effective in the treatment of splenic lymphoma with villous lymphocytes. Br J Haematol. 1997;99:158–161.10.1046/j.1365-2141.1997.3523168.x
   PubMed Web of Science ®Google Scholar
• Virchis A, Mehta A. Splenic lymphoma with villous lymphocytes (SLVL) responding to 2-chlorodeoxyadenosine (2-CDA). Br J Haematol. 1998;100:609.10.1046/j.1365-2141.1998.0636f.x
   PubMed Web of Science ®Google Scholar
• Lefrère F1, Hermine O, Belanger C, François S, Tilly H, de La Cour JC, et al. Fludarabine: an effective treatment in patients with splenic lymphoma with villous lymphocytes. Leukemia. 2000; 14:573–575.10.1038/sj.leu.2401710
   PubMed Web of Science ®Google Scholar
• Iannitto E, Minardi V, Calvaruso G, Ammatuna E, Florena AM, Mule A, et al. Deoxycoformycin (pentostatin) in the treatment of splenic marginal zone lymphoma (SMZL) with or without villous lymphocytes. Eur J Haematol. 2005;75:130–135.10.1111/ejh.2005.75.issue-2
   PubMed Web of Science ®Google Scholar
• Matutes E. Splenic marginal zone lymphoma with and without villous lymphocytes. Curr Treat Options Oncol. 2007 Apr;8(2):109–116.10.1007/s11864-007-0026-0
   PubMedGoogle Scholar
• Kalpadakis C, Pangalis GA, Dimopoulou MN, Vassilakopoulos TP, Kyrtsonis MC, Korkolopoulou P, et al. Rituximab monotherapy is highly effective in splenic marginal zone lymphoma. Hematol Oncol. 2007;25:127–131.10.1002/(ISSN)1099-1069
   PubMed Web of Science ®Google Scholar
• Hermine O, Lefrère F, Bronowicki JP, Mariette X, Jondeau K, Eclache-Saudreau V, et al. Regression of splenic lymphoma with villous lymphocytes after treatment of hepatitis C virus infection. N Engl J Med. 2002;347:89–94.10.1056/NEJMoa013376
   PubMed Web of Science ®Google Scholar
• Kelaidi C, Rollot F, Park S, Tulliez M, Christoforov B, Calmus Y, et al. Response to antiviral treatment in hepatitis C virus associated marginal zone lymphomas. Leukemia. 2004;18:1711–1716.10.1038/sj.leu.2403443
   PubMed Web of Science ®Google Scholar
• Cervetti G, Galimberti S, Andreazzoli F, Fazzi R, Cecconi N, Caracciolo F, et al. High efficacy of Rituximab in indolent HCV-related lymphoproliferative disorders associated with systemic autoimmune diseases. Clin Exp Rheumatol. 2005;23(6):877–880.
   PubMed Web of Science ®Google Scholar